Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation.
Audrey Le Floc'hJeanne AllinneKirsten NagashimaGeorge ScottDylan BirchardSeblewongel AsratYu BaiWei Keat LimJoel MartinTammy HuangTerra B PotockyJee H KimAshique RafiqueNicholas J PapadopoulosNeil StahlGeorge D YancopoulosAndrew J MurphyMatthew A SleemanJamie M OrengoPublished in: Allergy (2020)
Overall, these data support IL-4 and IL-13 as key drivers of type 2 inflammation and help provide insight into the therapeutic mechanism of dupilumab, a dual IL-4/IL-13 blocker, in multiple type 2 diseases.